PE20210111A1 - Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso - Google Patents
Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su usoInfo
- Publication number
- PE20210111A1 PE20210111A1 PE2020001553A PE2020001553A PE20210111A1 PE 20210111 A1 PE20210111 A1 PE 20210111A1 PE 2020001553 A PE2020001553 A PE 2020001553A PE 2020001553 A PE2020001553 A PE 2020001553A PE 20210111 A1 PE20210111 A1 PE 20210111A1
- Authority
- PE
- Peru
- Prior art keywords
- fusion protein
- recombinant fusion
- nrg
- compositions
- methods
- Prior art date
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract 4
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 title 1
- 102000055650 human NRG1 Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000048238 Neuregulin-1 Human genes 0.000 abstract 2
- 108090000556 Neuregulin-1 Proteins 0.000 abstract 2
- 230000003293 cardioprotective effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
Abstract
La presente invencion hace referencia a una proteina de fusion recombinante que comprende un fragmento de neuregulina-1 (NRG-1) de proteina cardioprotectora fusionada a una estructura de anticuerpo monoclonal (mAb) y a un metodo para el tratamiento de una enfermedad o afeccion en un sujeto que lo necesita que comprende la administracion de una cantidad terapeuticamente eficaz de la proteina de fusion recombinante o la composicion farmaceutica que comprende la proteina de fusion recombinante descrita en la presente
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862656246P | 2018-04-11 | 2018-04-11 | |
PCT/US2019/026889 WO2019200033A1 (en) | 2018-04-11 | 2019-04-11 | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210111A1 true PE20210111A1 (es) | 2021-01-19 |
Family
ID=66484143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001553A PE20210111A1 (es) | 2018-04-11 | 2019-04-11 | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso |
Country Status (21)
Country | Link |
---|---|
US (3) | US11046741B2 (es) |
EP (2) | EP4361177A2 (es) |
JP (2) | JP2021535727A (es) |
KR (1) | KR20210022542A (es) |
CN (1) | CN113166218A (es) |
AU (2) | AU2019252262B2 (es) |
BR (1) | BR112020020646A2 (es) |
CA (1) | CA3096420A1 (es) |
CL (1) | CL2020002621A1 (es) |
CO (1) | CO2020012621A2 (es) |
DK (1) | DK3774859T3 (es) |
EA (1) | EA202092458A1 (es) |
FI (1) | FI3774859T3 (es) |
IL (1) | IL277790A (es) |
MX (1) | MX2020010740A (es) |
PE (1) | PE20210111A1 (es) |
PH (1) | PH12020551648A1 (es) |
PT (1) | PT3774859T (es) |
SG (1) | SG11202009831UA (es) |
TW (1) | TWI834654B (es) |
WO (1) | WO2019200033A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046741B2 (en) | 2018-04-11 | 2021-06-29 | Salubris Biotherapeutics, Inc. | Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof |
AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
US20230057622A1 (en) * | 2019-09-16 | 2023-02-23 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Recombinant Human Neuregulin Derivatives and Use Thereof |
WO2023178086A1 (en) * | 2022-03-15 | 2023-09-21 | Salubris Biotherapeutics, Inc. | Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
AU2002304965A1 (en) * | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
WO2006017184A2 (en) * | 2004-07-09 | 2006-02-16 | Wayne State University | HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING |
US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
US20070213264A1 (en) * | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
CN101827860A (zh) | 2007-10-16 | 2010-09-08 | 西福根有限公司 | 包含最佳化her1和her3多聚体的组合物及其使用方法 |
US20090226435A1 (en) * | 2008-03-08 | 2009-09-10 | Sanjay Khare | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
SG192496A1 (en) * | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 binding proteins and uses thereof |
JP5743898B2 (ja) | 2008-11-28 | 2015-07-01 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド | ニューレグリンペプチド及びその使用 |
AU2010303443A1 (en) * | 2009-10-09 | 2012-04-19 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-Her 3 antibodies |
CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
US9029328B2 (en) * | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
JP6449876B2 (ja) * | 2013-11-07 | 2019-01-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューレグリンに対して非競合的でアロステリックな抗ヒトher3抗体及びその使用 |
CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
PT3129063T (pt) * | 2014-04-10 | 2021-04-01 | Daiichi Sankyo Europe Gmbh | Conjugado anticorpo anti-her3-fármaco |
CA2959716A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
IL260937B2 (en) | 2016-02-06 | 2024-07-01 | Epimab Biotherapeutics Inc | FABS antibodies one by one and their uses |
BR112019005001A2 (pt) | 2016-09-15 | 2019-06-04 | Univ Stuttgart | proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral |
US11046741B2 (en) | 2018-04-11 | 2021-06-29 | Salubris Biotherapeutics, Inc. | Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof |
-
2019
- 2019-04-11 US US16/381,206 patent/US11046741B2/en active Active
- 2019-04-11 JP JP2020556258A patent/JP2021535727A/ja active Pending
- 2019-04-11 TW TW108112630A patent/TWI834654B/zh active
- 2019-04-11 FI FIEP19723548.4T patent/FI3774859T3/fi active
- 2019-04-11 WO PCT/US2019/026889 patent/WO2019200033A1/en active Application Filing
- 2019-04-11 PT PT197235484T patent/PT3774859T/pt unknown
- 2019-04-11 EP EP24161673.9A patent/EP4361177A2/en active Pending
- 2019-04-11 EP EP19723548.4A patent/EP3774859B1/en active Active
- 2019-04-11 KR KR1020207032449A patent/KR20210022542A/ko unknown
- 2019-04-11 EA EA202092458A patent/EA202092458A1/ru unknown
- 2019-04-11 MX MX2020010740A patent/MX2020010740A/es unknown
- 2019-04-11 BR BR112020020646-6A patent/BR112020020646A2/pt unknown
- 2019-04-11 CN CN201980025049.3A patent/CN113166218A/zh active Pending
- 2019-04-11 CA CA3096420A patent/CA3096420A1/en active Pending
- 2019-04-11 PE PE2020001553A patent/PE20210111A1/es unknown
- 2019-04-11 AU AU2019252262A patent/AU2019252262B2/en active Active
- 2019-04-11 DK DK19723548.4T patent/DK3774859T3/da active
- 2019-04-11 SG SG11202009831UA patent/SG11202009831UA/en unknown
-
2020
- 2020-10-02 PH PH12020551648A patent/PH12020551648A1/en unknown
- 2020-10-05 IL IL277790A patent/IL277790A/en unknown
- 2020-10-09 CL CL2020002621A patent/CL2020002621A1/es unknown
- 2020-10-21 CO CONC2020/0012621A patent/CO2020012621A2/es unknown
-
2021
- 2021-05-21 US US17/327,494 patent/US11718652B2/en active Active
-
2023
- 2023-06-13 US US18/333,797 patent/US20230322877A1/en active Pending
- 2023-06-14 JP JP2023097663A patent/JP2023134436A/ja active Pending
- 2023-12-20 AU AU2023285793A patent/AU2023285793A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019252262A1 (en) | 2020-10-22 |
US20230322877A1 (en) | 2023-10-12 |
AU2023285793A1 (en) | 2024-01-18 |
JP2021535727A (ja) | 2021-12-23 |
FI3774859T3 (fi) | 2024-05-24 |
TW201945389A (zh) | 2019-12-01 |
US11046741B2 (en) | 2021-06-29 |
IL277790A (en) | 2020-11-30 |
CO2020012621A2 (es) | 2020-12-21 |
CA3096420A1 (en) | 2019-10-17 |
EP3774859A1 (en) | 2021-02-17 |
US20200010522A1 (en) | 2020-01-09 |
CL2020002621A1 (es) | 2021-06-11 |
AU2019252262B2 (en) | 2023-10-05 |
TWI834654B (zh) | 2024-03-11 |
EA202092458A1 (ru) | 2021-02-08 |
BR112020020646A2 (pt) | 2021-02-23 |
DK3774859T3 (da) | 2024-05-27 |
MX2020010740A (es) | 2021-01-20 |
EP4361177A2 (en) | 2024-05-01 |
CN113166218A (zh) | 2021-07-23 |
SG11202009831UA (en) | 2020-11-27 |
KR20210022542A (ko) | 2021-03-03 |
US20210347841A1 (en) | 2021-11-11 |
PT3774859T (pt) | 2024-05-27 |
EP3774859B1 (en) | 2024-03-13 |
WO2019200033A1 (en) | 2019-10-17 |
JP2023134436A (ja) | 2023-09-27 |
PH12020551648A1 (en) | 2021-07-26 |
US11718652B2 (en) | 2023-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210111A1 (es) | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso | |
CL2020003096A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
PE20091449A1 (es) | Proteinas de union a antigenos | |
PE20180120A1 (es) | Proteinas de union a icos | |
CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
PE20190976A1 (es) | Anticuerpos de union a cd3 | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
CL2020001619A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. (divisional solicitud 201903095) | |
BR112018072915A2 (pt) | peptídeo cíclico isolado e composição farmacêutica | |
ECSP21010450A (es) | Anticuerpos antisortilina y métodos para su uso | |
BR112022009273A2 (pt) | Imunoglobulinas modificadas para direcionar depósitos amiloides | |
EA201892548A1 (ru) | Антитела к альфа-синуклеину и их применение | |
GT200600182A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos | |
CL2008002668A1 (es) | Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp. | |
BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
AR085198A1 (es) | Composicion farmaceutica | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
RU2013105769A (ru) | Биологические материалы и их применение | |
HRP20231650T1 (hr) | Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka | |
MX2023013050A (es) | Proteinas de fusion anticuerpo-peptido para el tratamiento de trastornos amiloides. | |
WO2017191327A3 (en) | Her-2 binding antibodies | |
BR112021009912A2 (pt) | Proteína de ligação a alfa receptor de folato, composição, e, método para produção da proteína de ligação a folr1 | |
TW202426470A (zh) | 人神經調節蛋白-1(nrg-1)重組融合蛋白組成物及其使用方法 | |
AR125589A1 (es) | Métodos para el tratamiento de la enfermedad ocular tiroidea |